Sanofi stock: third-quarter results due October 30 before the Xetra open
Published on 10/26/2026 at 08:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSReporting date and business model
- Sanofi will review its third-quarter 2026 results on October 30, 2026.
- Sanofi researches, develops, manufactures and markets prescription medicines and vaccines.
- Sanofi stock trades pre-market at EUR 74.50 at 8:29 a.m. CET at Lang & Schwarz on October 26, 2026.
Sanofi will review its third-quarter 2026 results on October 30, 2026, during a live webcast for the financial community, according to the company’s investor-relations calendar. The session is scheduled for 1:30 p.m. to 2:30 p.m. CET and will include a management presentation followed by a question-and-answer session.
Third-quarter results on October 30
Sanofi’s upcoming reporting date falls within the next ten trading days. The company has identified the event as its third-quarter 2026 results review and said that an aide-mémoire is available through its investor-relations materials, which also list the webcast timing.
Ahead of the Xetra open
At 8:29 a.m. CET on October 26, 2026, Lang & Schwarz quoted Sanofi stock at EUR 74.50. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Sanofi stock.
How Sanofi makes its money
Sanofi researches, develops, manufactures and markets prescription medicines and vaccines in the healthcare market, according to its investor-relations materials. The next scheduled company event is the third-quarter results webcast on October 30, 2026, at 1:30 p.m. CET. Market context: Market report CAC 40.
